drugset / Trial / NCT05727371
Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
In this clinical trial the investigator assess the safety and efficacy of a single injection of a combination of cross-linked hyaluronic acid (HA) with autologous platelet-rich plasma (PRP) obtained with the RegenMatrix medical device to improve symptoms of moderate to severe knee osteoarthitis (grade III-IV Kellgren-Lawrence).
Timeline
- Start
- 2023-08-21
- Primary completion
- 2026-02-28
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Platelet Rich Plasma | Other / unclassified | — | Other |
| Subject | cross-linked hyaluronic acid | Unknown | — | Other |